This website is for healthcare providers

Please click on the agreement button below to acknowledge that you are a healthcare provider.

Menu

The previous formulation of Norliqva (NDC Code: 46287-035-15) has been discontinued.

View full prescribing
information here

Norliqva® is the first and only FDA-approved oral liquid solution of amlodipine and is now available in a new alcohol free reformulation for patients 6 years and older.

Contact your wholesaler to order Alcohol Free Norliqva today and use the new NDC below

150mL bottle | New NDC: 46287-037-01

Why Norliqva?

  • It's the first & only FDA-approved liquid solution of amlodipine for hypertension and coronary artery disease.
  • It's an alcohol free liquid formulation in a mixed berry flavor for adults and children six years and older.
  • No refrigeration is required, alleviating the added burden of refrigeration for caregivers and patients.
  • No shaking is required, which makes Norliqva a convenient, ready-to-use oral solution.

Featured Benefits

  • FDA-approved ready-made oral solution formulation for adults and children 6 and older
  • Tested to ensure potency and consistency in dosing
  • Stable 24-month shelf life, no refrigeration required
  • Child friendly mixed berry flavor
  • No additional preparation or shaking required by pharmacist / patient / caregiver

Norliqva Educational Resources

Before You Crush/Compound
Consider the Following

  • Effectiveness: Compounded drugs have not been evaluated by the FDA for safety, effectiveness, or quality prior to being dispensed to patients.¹
  • Quality Violations: In FDA warning letters to compounding pharmacies regarding cGMP violations, 92% identified adulterated product, frequently involving insanitary conditions.²
  • Costly Protocols: Crushing can require expensive safety protocols that take up valuable staff time.
  • Shelf Life: Compounded products can have variable and short shelf lives.³

Additional Concerns Regarding Compounding

  • The FDA has issued guidance on compounding and advises against use when an FDA-approved version exists.¹
  • Pharmacies creating compounded versions of FDA-approved medications may violate the Federal Food, Drug, and Cosmetic Act (FDCA).¹

DID YOU KNOW? Prescribing Norliqva, an FDA-approved, ready-made oral solution, removes the concerns that can arise from crushing and compounding tablets.

Administering medication to children presents unique challenges that can impact patient outcomes.

Common Pediatric Challenges Reported by Caregivers:

  • Difficulty Swallowing Tablets: Most children are typically around 10 years old before they can reliably swallow tablets.⁴
  • Personal Preference: Some caregivers have a preference for liquid options.⁵
  • Taste: 57.9% of U.S. caregivers report children regularly or always refuse medications due to bitter taste.⁶
  • Medication Adherence: Over 80% of providers globally confirm bitter taste impacts medication adherence.⁶

These challenges can be mitigated with Norliqva, an FDA-approved oral liquid solution. Norliqva provides a ready-to-use, mixed berry flavored liquid solution with no refrigeration or shaking required for ease of use.

In addition to pediatric patients, other patient populations can also benefit from Norliqva such as:

  • Geriatric patients
  • Patients with an inability to swallow
  • Patients with dysphagia or difficulty swallowing
  • Patients with comorbid conditions that affect swallowing

Patients pay as
little as $0*

on each prescription
using the EasyPay Card

Click below to get your EasyPay Copay Card now or call 1-844-567-9503

Terms and Conditions

* Void where prohibited by law. CMP Pharma reserves the right to rescind, revoke or amend this program without notice. Offer not valid for patients eligible for benefits under Medicaid (including Medicaid managed care), Medicare, TRICARE, Veterans Affairs, FEHBP, or similar state or federal programs. Offer void where prohibited, taxed, or otherwise restricted. Offer good only in the U.S.A. No generic substitution with this offer.

Important Safety Information

INDICATIONS AND USAGE

NORLIQVA is a calcium channel blocker for the treatment of:

HYPERTENSION

NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CORONARY ARTERY DISEASE

  • Chronic Stable Angina
  • Vasospastic Angina (Prinzmetal’s or Variant Angina)
  • Angiographically Documented Coronary Artery Disease In patients without heart failure or an ejection fraction <40%

CONTRAINDICATIONS

NORLIQVA is contraindicated in patients with sensitivity to amlodipine.

WARNINGS AND PRECAUTIONS/ADVERSE REACTIONS

NORLIQVA may cause the following conditions.

  • Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely.
  • Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORLIQVA, particularly in patients with severe obstructive coronary artery disease.
  • Titrate slowly in patients with severe hepatic impairment.

Most common adverse reactions to amlodipine were edema, dizziness, flushing and palpitation which occurred in a dose related manner. Other adverse reactions not clearly dose-related but reported with an incidence >1.0% are fatigue and nausea.

Talk to your healthcare provider about other possible side effects with NORLIQVA. To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Do not exceed doses greater than 20 mg daily of simvastatin.

  • CYP3A Inhibitors: Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.
  • CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.
  • Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.
  • Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co- administered.

DOSAGE AND ADMINISTRATION

NORLIQVA is an oral solution: 1 mg/mL. Adult recommended starting dose: 5 mg orally once daily with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg orally once daily. Pediatric starting dose: 2.5 mg to 5 mg orally once daily.

Please see Prescribing Information for additional safety information.

1 FDA Guidance, “Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the FD&C Act” (January 2018); 21 CFR § 503A. 2 Isra Dmour. Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022. (2022 Nov 16 ,https://pmc.ncbi.nlm.nih.gov/articles/PMC9666930/ – (In a study of 141 FDA warning letters) 3 United States Pharmacopeia. (2022, November 1). USP General Chapters on compounding nonsterile and sterile preparations [Updated]. 4 Christine De Maria, Marie-Thérèse Lussier, Jana Bajcar. What do children know about medications? PMCID: PMC3056675  PMID: 21520667 https://pmc.ncbi.nlm.nih.gov/articles/PMC3056675/ 5 Yana Gvozdeva, Radiana Staynova. Choosing the “Ideal” Oral Dosage Form for Pediatric Patients: Parents’ Perspectives on Children’s Preferences with a Focus on Orodispersible Tablets. PMCID: PMC12468621  PMID: 41007052 https://pmc.ncbi.nlm.nih.gov/articles/PMC12468621/ 6 El-Sahn, M., Elliott, R., El-Sahn, M., Lucas, I., Kong, K., Walsh, J., & Lucas, J. (2025, April 22). Poor-tasting pediatric medicines: part 2. Exploring caregiver and healthcare provider values and preferences for a novel taste-blocker product to improve acceptability. Frontiers in Drug Delivery, 5, 1555522. https://doi.org/10.3389/fddev.2025.1555522 https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2025.1555522/full

© 2026 CMP Pharma | Norliqva® Amlodipine Oral Solution | All rights reserved.

Indication

Norliqva is a calcium channel blocker for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Norliqva is indicated for the treatment of coronary artery disease: chronic stable angina, vasospastic angina (Prinzmetal’s or variant angina), and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction <40%.

Important Safety Information

NORLIQVA is contraindicated in patients with sensitivity to amlodipine.

Read More about Norliqva's Safety Information